NOTES Companies Sing an Upbeat Tune
This article was originally published in Start Up
Executive Summary
There was an almost dot-com-like euphoria about NOTES at 2007's annual meetings of endoscopists and surgeons. NOTES (natural orifice translumenal endoscopic surgery) is being described as a revolution in minimally invasive surgery, incisionless surgery, or at the very least, a major advance over laparoscopy. It represents a billion-dollar category not yet dominated by the companies that gained preeminence in the $4 billion worldwide laparoscopy market. But most companies in the area agree that the NOTES revolution isn't going to happen overnight. The challenge for today is to create products and technologies for procedures that can happen in high volume in the near term, while waiting for more advanced NOTES procedures to come about.
You may also be interested in...
EndoGastric Solutions Rewrites Playbook In Bid To Build GERD Business
Founded in 2001, EndoGastric Solutions Inc., a mature medical device company with $140 million in venture backing, hasn’t been able to secure a reliable source of reimbursement dollars for its EsophyX endoscopic treatment for GERD. Under new management, EGS is recommitting itself to collecting necessary clinical data and operating as a lean start-up as it makes its case for coverage and reimbursement with insurers.
The Future of Laparoscopy: Single Incision, NOTES and Robots
The skill sets of laparoscopy, endoscopy, robotics and even interventional cardiology are all converging to create least invasive surgeries that take laparoscopy as a point of departure but change how surgeons access the abdominal cavity. Start-ups are innovating to supply the new surgical instruments.
What's Next for NOTES? An Interview with Santiago Horgan, MD
Medtech Insight interviews Santiago Horgan, MD, professor of surgery at the University of California, San Deigo School of Medicine and a leader in the emerging field of NOTES.